<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width,initial-scale=1" />
  <title>T2D Injectable Therapy CDS — Algorithm</title>
  <link rel="icon" href="data:,">
  <link rel="stylesheet" href="styles.css" />
  <style>
    .doc h1 { margin: 0 0 10px 0; font-size: 20px; }
    .doc p, .doc li { color: #1a2233; }
    .doc code { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono","Courier New", monospace; }

    .nav { display:flex; gap:10px; margin-bottom:14px; flex-wrap:wrap; }
    .nav a {
      font-size:13px; color: var(--accent); text-decoration:none;
      border:1px solid var(--line); background:#fff; padding:8px 12px;
      border-radius:999px; font-weight:600;
    }
    .nav a:hover { filter: brightness(0.98); }

    .figure { border:1px solid var(--line); border-radius: var(--radius); background:#fff; padding:12px; overflow:auto; }
    .figure img { width:100%; height:auto; display:block; }
    .caption { margin-top:8px; font-size:12px; color: var(--muted); }

    .doc h2 { margin-top: 16px; font-size: 16px; }
    .doc h3 { margin-top: 14px; }
    .doc p { font-size:14px; line-height:1.55; margin: 10px 0; }
    .doc strong { color: var(--accent); }

    .node { border-left: 3px solid rgba(31,58,138,.35); padding-left: 12px; margin: 12px 0; }
    .version { display:flex; gap:10px; flex-wrap:wrap; margin-top: 8px; color: var(--muted); font-size: 12px; }
    .pill { border:1px solid var(--line); background:#fff; border-radius:999px; padding:6px 10px; }
  </style>
</head>

<body>
  <header class="topbar">
    <div class="container">
      <div class="brand">
        <div class="brand__title">T2D Injectable Therapy CDS</div>
        <div class="brand__subtitle">Algorithm description (public page)</div>
      </div>
      <div class="badge">Algorithm • v1</div>
    </div>
  </header>

  <main class="container">
    <section class="card doc">
      <div class="nav">
        <a href="./index.html">Open tool</a>
        <a href="./algorithm.html">Algorithm</a>
      </div>

      <h1>Injectable therapy decision algorithm</h1>

      <p>
        This page explains the decision logic used by the CDS prototype for adults with
        <strong>type 2 diabetes (T2D)</strong>. The goal is transparency: the tool generates a recommendation
        plus rationale and next steps.
      </p>

      <div class="version">
        <span class="pill"><strong>Algorithm version:</strong> v1 (MVP)</span>
        <span class="pill"><strong>Scope:</strong> first injectable, intensification, simplification</span>
        <span class="pill"><strong>Engine:</strong> <code>py/engine.py</code></span>
      </div>

      <hr class="sep" />

      <h2>Decision tree (diagram)</h2>

      <div class="figure">
        <img src="assets/decision-tree.png" alt="Decision tree: T2D injectable therapy algorithm">
        <div class="caption">
          Figure. Decision-tree overview. Country selection is the first node; Jordan disables FRC;
          Turkey shows reimbursement note for BMI &lt; 35 when FRC is recommended.
        </div>
      </div>

      <hr class="sep" />

      <h2>Textual description of the algorithm</h2>

      <div class="node">
        <h3>1) Country selection (first node)</h3>
        <p>
          The algorithm first applies a <strong>country profile</strong> (RU, TR, LB, JO, IQ, EU, US, OTHER).
          This profile may affect availability assumptions and country-specific notes.
        </p>
        <ul>
          <li><strong>Jordan (JO):</strong> FRC (iGlarLixi) is treated as <strong>not available</strong>.</li>
          <li><strong>Turkey (TR):</strong> if FRC is recommended and BMI &lt; 35, show a comment:
            “reimbursement often requires BMI ≥35; otherwise may be out-of-pocket” (comment only).
          </li>
        </ul>
      </div>

      <div class="node">
        <h3>2) Severe hyperglycaemia</h3>
        <p>
          <strong>If</strong> catabolic symptoms are present <strong>OR</strong> HbA1c ≥ 10%,
          recommend <strong>insulin start or urgent insulin intensification</strong>.
        </p>
        <p class="caption">
          Rationale: rapid glycaemic control is prioritised in severe hyperglycaemia/catabolic context to reduce acute risk.
        </p>
      </div>

      <div class="node">
        <h3>3) Simplification / de-intensification (complex insulin regimens)</h3>
        <p>
          <strong>If</strong> the patient is on <strong>basal-bolus</strong> or <strong>premix</strong> insulin
          and has <strong>recurrent hypoglycaemia</strong> or <strong>high regimen complexity/adherence issues</strong>:
        </p>
        <ul>
          <li><strong>If FRC is available</strong> (and not Jordan) → <strong>switch to FRC (iGlarLixi)</strong>.</li>
          <li><strong>Otherwise</strong> → simplify within insulin options.</li>
        </ul>
        <p class="caption">
          Rationale: de-intensification can be appropriate when hypoglycaemia risk or treatment burden outweighs benefit.
        </p>
      </div>

      <div class="node">
        <h3>4) Intensification on basal insulin</h3>
        <p><strong>If</strong> the patient is on <strong>basal insulin</strong> and HbA1c remains above target:</p>
        <ol>
          <li><strong>If GLP-1 RA is available</strong> → add GLP-1 RA to basal insulin.</li>
          <li><strong>Else if FRC is available</strong> (and not Jordan) → switch basal insulin to FRC (iGlarLixi).</li>
          <li><strong>Else</strong> → add prandial insulin (basal-plus strategy, stepwise escalation).</li>
        </ol>
        <p class="caption">
          Rationale: GLP-1 RA is typically preferred before adding mealtime insulin when feasible; FRC provides basal+postprandial control with one injection.
        </p>
      </div>

      <div class="node">
        <h3>5) First injectable selection (no current injectable therapy)</h3>

        <p><strong>A. Cardiorenal disease (ASCVD / HF / CKD):</strong></p>
        <ul>
          <li>If GLP-1 RA available → <strong>start GLP-1 RA</strong>.</li>
          <li>Otherwise → <strong>start basal insulin</strong>.</li>
        </ul>

        <p><strong>B. Obesity-driven approach (BMI ≥ 30):</strong></p>
        <ul>
          <li>If GLP-1 RA available → <strong>start GLP-1 RA</strong>.</li>
        </ul>

        <p><strong>C. Higher HbA1c without catabolic symptoms:</strong></p>
        <ul>
          <li>If HbA1c &gt; 9 and FRC available (not Jordan) → <strong>start FRC (iGlarLixi)</strong>.</li>
        </ul>

        <p><strong>D. Default rule:</strong></p>
        <ul>
          <li>If GLP-1 RA available → <strong>start GLP-1 RA</strong>.</li>
          <li>Otherwise → <strong>start basal insulin</strong>.</li>
        </ul>
      </div>

      <hr class="sep" />

      <h2>Disclaimer</h2>
      <p class="caption">
        This tool is a clinical decision-support prototype for internal evaluation. It does not replace clinical judgement,
        local guidance, institutional policies, or product labels. Always individualise therapy.
      </p>
    </section>
  </main>
</body>
</html>
